SNHG15‐mediated feedback loop interplays with HNRNPA1/SLC7A11/GPX4 pathway to promote gastric cancer progression

Abstract

AbstractDysregulation of long noncoding RNA (lncRNA) expression plays a pivotal role in the initiation and progression of gastric cancer (GC). However, the regulation of lncRNA SNHG15 in GC has not been well studied. Mechanisms for ferroptosis by SNHG15 have not been revealed. Here, we aimed to explore SNHG15‐mediated biological functions and underlying molecular mechanisms in GC. The novel SNHG15 was identified by analyzing RNA‐sequencing (RNA‐seq) data of GC tissues from our cohort and TCGA dataset, and further validated by qRT‐PCR in GC cells and tissues. Gain‐ and loss‐of‐function assays were performed to examine the role of SNHG15 on GC both in vitro and in vivo. SNHG15 was highly expressed in GC. The enhanced SNHG15 was positively correlated with malignant stage and poor prognosis in GC patients. Gain‐ and loss‐of‐function studies showed that SNHG15 was required to affect GC cell growth, migration and invasion both in vitro and in vivo. Mechanistically, the oncogenic transcription factors E2F1 and MYC could bind to the SNHG15 promoter and enhance its expression. Meanwhile, SNHG15 increased E2F1 and MYC mRNA expression by sponging miR‐24‐3p. Notably, SNHG15 could also enhance the stability of SLC7A11 in the cytoplasm by competitively binding HNRNPA1. In addition, SNHG15 inhibited ferroptosis through an HNRNPA1‐dependent regulation of SLC7A11/GPX4 axis. Our results support a novel model in which E2F1‐ and MYC‐activated SNHG15 regulates ferroptosis via an HNRNPA1‐dependent modulation of the SLC7A11/GPX4 axis, which serves as the critical effectors in GC progression, and provides a new therapeutic direction in the treatment of GC.